NorthCrest Asset Manangement LLC Sells 39,374 Shares of Bristol-Myers Squibb (NYSE:BMY)

NorthCrest Asset Manangement LLC lowered its stake in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 25.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 114,959 shares of the biopharmaceutical company's stock after selling 39,374 shares during the quarter. NorthCrest Asset Manangement LLC's holdings in Bristol-Myers Squibb were worth $6,502,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. PKO Investment Management Joint Stock Co purchased a new position in Bristol-Myers Squibb in the fourth quarter valued at about $905,000. Centaurus Financial Inc. lifted its position in Bristol-Myers Squibb by 11.5% in the fourth quarter. Centaurus Financial Inc. now owns 12,175 shares of the biopharmaceutical company's stock worth $689,000 after purchasing an additional 1,256 shares during the period. Anchor Pointe Wealth Management LLC bought a new position in Bristol-Myers Squibb in the fourth quarter worth $234,000. Mattson Financial Services LLC lifted its position in shares of Bristol-Myers Squibb by 3,318.2% during the 4th quarter. Mattson Financial Services LLC now owns 752 shares of the biopharmaceutical company's stock worth $39,000 after buying an additional 730 shares during the period. Finally, Wood Tarver Financial Group LLC bought a new position in shares of Bristol-Myers Squibb during the 4th quarter worth approximately $38,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol-Myers Squibb Stock Performance

Shares of NYSE:BMY traded up $0.48 during trading on Monday, reaching $48.76. 13,501,505 shares of the stock were exchanged, compared to its average volume of 13,071,409. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $63.33. The firm has a market cap of $99.23 billion, a PE ratio of -11.03, a PEG ratio of 2.07 and a beta of 0.39. The stock has a 50-day moving average price of $50.28 and a 200-day moving average price of $55.29. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping the consensus estimate of $1.50 by $0.30. The business had revenue of $11.20 billion for the quarter, compared to the consensus estimate of $10.77 billion. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The firm's revenue was down 5.6% compared to the same quarter last year. During the same period last year, the company earned ($4.40) EPS. Research analysts expect that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Insider Activity at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat purchased 4,250 shares of the firm's stock in a transaction on Friday, April 25th. The stock was purchased at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the acquisition, the executive vice president now owns 83,513 shares in the company, valued at approximately $3,973,548.54. The trade was a 5.36% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.09% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on BMY shares. William Blair reaffirmed a "market perform" rating on shares of Bristol-Myers Squibb in a report on Friday, April 25th. The Goldman Sachs Group restated a "neutral" rating and issued a $55.00 price target (down from $67.00) on shares of Bristol-Myers Squibb in a research report on Tuesday, April 8th. Argus upgraded Bristol-Myers Squibb to a "hold" rating in a report on Friday, April 25th. Piper Sandler started coverage on Bristol-Myers Squibb in a report on Tuesday, April 22nd. They set an "overweight" rating and a $65.00 target price on the stock. Finally, UBS Group reduced their target price on Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a report on Friday, April 11th. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have given a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and an average target price of $58.00.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.